华熙生物科技股份有限公司股东减持股份结果公告

Group 1 - The major shareholder, Guoshou Chengda, held 28,936,504 shares of Huaxi Biological Technology Co., Ltd., accounting for 6.01% of the total share capital before the reduction plan [2] - The reduction plan involved a maximum of 9,633,564 shares, representing up to 2.00% of the total share capital, with a maximum of 4,816,782 shares to be reduced through both centralized bidding and block trading [3] - As of January 15, 2026, Guoshou Chengda completed the reduction of 9,633,564 shares, with 4,816,782 shares reduced through centralized bidding and 4,816,782 shares through block trading [3][5] Group 2 - The reduction plan was disclosed on November 5, 2025, and the reduction period was set from November 26, 2025, to February 23, 2026 [3] - The actual reduction adhered to relevant laws and regulations, and there were no violations of the reduction plan or other commitments [6]